- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06070428
Project 4: ACHIEVE PATHFINDER (PATHFINDER)
ACHIEVE GREATER: Addressing Cardiometabolic Health Inequities by Early PreVEntion in the GREAT LakEs Region Project 4: Portable Air Cleaners to Treat Heart Failure and Negate Disparities of Environment and Race (PATHFINDER)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Heart failure (HF) is one of the most common, costly, and deadly diseases affecting humans. Health disparities persist whereby HF-related morbidity and mortality are greater in Black populations for a number of reasons yet to be fully understood. While the distribution of multiple negative social determinants of health (SDoH) certainly plays a key role, growing evidence further implicates an outsized adverse impact from environmental factors among urban dwelling populations. In this regard, a number of studies show that air pollutants adversely impact HF and its prognosis. As such, the investigators believe that air pollution is a form of environmental racism and a significant contributor to poor outcomes among HF patients in Detroit, including an unacceptably high rate of death or rehospitalization (22% based on Henry Ford Health [HFH] data for 2022) at 90-days post-discharge. To combat this problem, the investigators propose to test the effectiveness of portable air cleaners (PACs), an emerging therapeutic intervention, that the investigators hypothesize will reduce personal-level exposure to PM2.5 resulting in improved clinical outcomes for HF patients.
Patients will be enrolled at hospital discharge and randomly assigned to active PAC vs. sham PAC (a PAC without a HEPA filter inside it). Two PACs will be given to each patient to place in the home after discharge (one in bedroom and one in living space). The study will also provide one PM2.5 sensor for each participant home.
Follow-up in-person visits will be scheduled at 30 and 90- days after randomization and will be completed to draw blood for biomarkers, measure blood pressure, health status (Kansas City Cardiomyopathy Questionnaire, KCCQ), functional status (6 minute walk distance), and assess for occurrence of clinical events (i.e. re-hospitalization or death). The biomarkers include measures of heart failure disease activity (NTproBNP), inflammation (CRP) and cardiac injury (high sensitivity troponin).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Whitney Cabral, MS
- Phone Number: 313-874-1887
- Email: wcabral1@hfhs.org
Study Contact Backup
- Name: Samantha Hochstadt, MS
- Phone Number: 313-874-7112
- Email: shochst1@hfhs.org
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health
-
Contact:
- Whitney Cabral
- Phone Number: 313-874-1887
- Email: WCABRAL1@hfhs.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Currently hospitalized with plan to be discharged to home
- Primary discharge diagnosis heart failure
- BNP>300 ng/L or NTproBNP>1000 ng/L during hospitalization or within 1 month prior to screening.
- Expected ability to fully participate in study (can tolerate study processes, no long travel)
Exclusion Criteria:
- Hemodialysis dependent
- Life expectancy of less than one year
- Inability to provide written informed consent
- Age less than 18 years old
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: PAC Intervention Arm
Participants randomized to the interventional arm will be given 2 PAC units with HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor. Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed. Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters. |
Patients randomized to receive the intervention will receive two PACs fitted with True HEPA filters.
Other Names:
|
Sham Comparator: Control non-interventional Arm
Participants randomized to the non-interventional arm will be given 2 PAC units without HEPA filters inside to be used in the home: one in the room patient sleeps in, the other in the living area of the home. Participants will also be given an air quality monitor. Study staff will educate the patient on use of the filters and monitor. Patients will be seen in clinic for 30-day and 90-day follow-up visits. Blood pressure, blood draw for biomarker levels, 6-minute walk distance, and questionnaires will be completed. Patients will be allowed to keep the PAC at the end of the trial and will be informed at that time how to purchase additional filters. |
Patients randomized to the control non-interventional arm will receive two PACs with no filters inserted.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The impact of PAC use for 90 days after hospital discharge for HF compared to sham on NTproBNP level.
Time Frame: Baseline at hospital discharge to 90 days.
|
Change in NTproBNP from baseline to 90 days.
This will be determined by comparing the NTproBNP value at the 90-day follow up visit versus the baseline NTproBNP value measured from blood draw at enrollment/randomization visit (within 48 hours of hospital discharge).
|
Baseline at hospital discharge to 90 days.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The effect of PAC use on home PM2.5 levels in active PAC group versus sham group
Time Frame: Baseline to 90 days
|
Each participant will be provided an indoor PM2.5 sensor to measure in-home PM2.5 levels
|
Baseline to 90 days
|
The effect of PAC use on clinical events (death) in the active PAC group versus sham group
Time Frame: Baseline to 90 days
|
Clinical events such as death will be monitored primarily by EMR data.
|
Baseline to 90 days
|
The effect of PAC use on clinical events (hospitalization) in the active PAC group versus sham group
Time Frame: Baseline to 90 days
|
Clinical events will be monitored primarily by EMR data, but patients will also be queried at study visits regarding hospitalization.
|
Baseline to 90 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of PAC on hsCRP
Time Frame: 30 and 90 days post-enrollment
|
hsCRP and hsTroponin will be measured at 30 and 90 days post-enrollment
|
30 and 90 days post-enrollment
|
Impact of PAC use on health status
Time Frame: Baseline, 30 and 90 days post enrollment
|
Change in health status will be evaluated by use of the Kansas City Cardiomyopathy Questionnaire (KCCQ) a validated health status tool for detecting clinically important changes.
The score will be represented on a 0-to-100 scale; lower scores represent more severe symptoms and scores of 100 represent no limitations.
|
Baseline, 30 and 90 days post enrollment
|
Impact of PAC on hsTroponin
Time Frame: 30 and 90 days post-enrollment
|
hsTroponin will be measured at 30 and 90 days post-enrollment
|
30 and 90 days post-enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Lanfear, MD, Henry Ford Health
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16658
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on PAC provision at hospital discharge
-
Ain Shams UniversityUnknownThe Effect of Early Versus Traditional Hospital Discharge for Women Undergoing Elective Cesarean SectionEgypt
-
CHU de Quebec-Universite LavalUnknown
-
The Cleveland ClinicCompleted
-
FHI 360Pathfinder InternationalCompleted
-
Cedars-Sinai Medical CenterNational Institute on Aging (NIA)Active, not recruitingPolypharmacy | Readmission | Nonadherence, PatientUnited States
-
University Hospital, ToulouseCompleted
-
University of AarhusTrygFonden, Denmark; Sygekassernes Helsefond; Region ZealandCompletedTotal Hip Replacement
-
Northwell HealthTerminatedRe-hospitalization HemodialysisUnited States
-
VA Office of Research and DevelopmentCompleted